Oxidized HDL in the intersection of HIV, immune activation and atherosclerosis
HIV、免疫激活和动脉粥样硬化交叉点中的氧化 HDL
基本信息
- 批准号:8719933
- 负责人:
- 金额:$ 17.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-08-12 至 2018-07-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAnti-Inflammatory AgentsAnti-inflammatoryAntioxidantsAntiviral AgentsAntiviral ResponseAntiviral TherapyAtherosclerosisAwardBiological MarkersBiometryCD4 Positive T LymphocytesCD8B1 geneCardiovascular DiseasesCardiovascular systemCause of DeathCell CommunicationCell membraneCellsCellular biologyChemotaxisChronicClinicalComplexDataDevelopmentDiseaseDrug FormulationsEventFoundationsGeneral PopulationGoalsHIVHIV InfectionsHIV-1High Density LipoproteinsImmuneImmune systemImmunityImmunologyIn VitroInfectionInflammationK-Series Research Career ProgramsLaboratoriesLifeLife Cycle StagesLinkLipidsLipoproteinsMediatingMediator of activation proteinMentorsMorbidity - disease ratePathogenesisPatientsPeptidesPersonsPharmaceutical PreparationsPlayProcessProductionPublic HealthPublishingReactive Oxygen SpeciesReportingResearchResearch ProposalsRoleScientistT-Cell ActivationT-LymphocyteTestingTrainingViralViremiaVirusWorkatherogenesiscardiovascular disorder riskcytotoxicdesignimmune activationimprovedin vivoinnovationmacrophagemimeticsmonocytemortalitynovelnovel strategiesnovel therapeutic interventionoutcome forecastoxidationoxidized lipidpatient populationprotective effectvirology
项目摘要
DESCRIPTION (provided by applicant): Cardiovascular disease (CVD) is becoming a major cause of death in persons with HIV-1 infection. The mechanisms that link HIV-1 infection, CVD and activation of the immune system associated with HIV infection (immune activation) remain unknown. High density lipoproteins (HDL) have key roles in moderating inflammation and immunity. HDL has generally protective effects against oxidized lipids and CVD, and has a normal potent antioxidant role. However, HDL is subject to continuous remodeling in vivo and during systemic inflammation it can be oxidized, lose its normal antioxidant functions, and become dysfunctional and pro-oxidant. We have recently shown that HIV-1 infected subjects have dysfunctional HDL that increases monocyte chemotaxis, a key event in atherogenesis, in vitro and that also is significantly associated with biomarkers of T cell activation and progressio of atherosclerosis in HIV-infected subjects. Therefore, a study to assess dysfunctional HDL as a possible mechanistic link and a new contributor to the increased rate of immune activation and CVD in HIV-1 infection is a novel approach in this patient population. This award application is intended to support the applicant's clinical scientist research career development award through mentoring, formal training in immunology, virology, lipidology and biostatistics. We hypothesize that a vicious cycle of HIV-induced immune activation, inflammation, production of oxidized HDL, and further immune activation may explain the increased rate of CVD in HIV infection. To test this hypothesis, we will determine the mechanisms that mediate the cross-talk between oxidized HDL and cells important for HIV-induced immune activation and atherogenesis (Aim 1). Previously published data have demonstrated HDL may have antiviral activity and that oxidized lipids may directly modulate immunity and affect HIV infectivity. In view of these data, in Aim 2, we will investigate whether oxidized HDL directly affects the life cycle of HIV-1 and leads to reduced antiviral responses of cytotoxic CD8 T cells and increased viremia that drives immune activation and inflammation. Finally, guided by our preliminary findings that administration of a drug that can mimic the function of normal HDL (HDL mimetic) may improve HDL function in vitro in HIV-1 infected subjects, we will investigate whether in vitro administration of HDL mimetics, can reduce HIV-induced immune activation and HIV-1 infectivity (Aims 1, 2). The data to be generated in the proposed study will allow to determine whether oxidized HDL is a novel mechanistic link between HIV-1, immune activation and atherosclerosis. The long-term goals of this research are to provide the foundation for further studies whether HDL mimetics can be used therapeutically in HIV infection.
RELEVANCE: HIV-infected patients receiving antiviral therapy die prematurely of cardiovascular disease (CVD), compared to the general population but the mechanisms that link HIV infection, CVD and activation of the immune system (immune activation) remain unknown. This research proposal is designed to investigate whether abnormal lipoproteins that are produced during systemic inflammation seen with HIV infection may mediate the cross-talk between HIV, the immune system and CVD. We anticipate that this 5-year study will improve our understanding of the pathogenesis of HIV-associated immune activation and CVD and these findings may initiate further studies to explore the efficacy of novel therapeutic interventions that might improve the prognosis of HIV-infected patients.
描述(由申请人提供):心血管疾病(CVD)已成为HIV-1感染患者的主要死亡原因。将HIV-1感染,CVD和与HIV感染相关的免疫系统激活(免疫激活)连接的机制尚不清楚。高密度脂蛋白(HDL)在调节炎症和免疫力中具有关键作用。 HDL通常具有针对氧化脂质和CVD的保护作用,并且具有正常的有效抗氧化作用。但是,HDL在体内进行连续重塑,在系统性炎症期间,它可以被氧化,失去其正常的抗氧化剂功能,并变得功能失调且促氧化剂。我们最近表明,HIV-1感染的受试者具有功能失调的HDL,它增加了单核细胞趋化性,这是动脉粥样硬化中的关键事件,体外,这也与HIV感染受试者的动脉粥样硬化和动脉粥样硬化的生物标志物显着相关。因此,一项评估功能失调的HDL作为可能的机理联系的研究,以及HIV-1感染中免疫激活率和CVD增加的新贡献者是该患者人群的一种新方法。该奖项申请旨在通过指导,免疫学,病毒学,脂肪学和生物统计学方面的指导,正规培训来支持申请人的临床科学家研究职业发展奖。我们假设HIV诱导的免疫激活,炎症,氧化HDL的产生以及进一步的免疫激活的恶性循环可以解释HIV感染中CVD的增加。为了检验这一假设,我们将确定介导氧化的HDL和细胞之间对HIV诱导的免疫激活和动脉粥样硬化很重要的细胞之间的串扰的机制(AIM 1)。先前发表的数据表明,HDL可能具有抗病毒活性,并且氧化脂质可能直接调节免疫力并影响HIV感染性。鉴于这些数据,在AIM 2中,我们将研究氧化的HDL是否直接影响HIV-1的生命周期,并导致细胞毒性CD8 T细胞的抗病毒反应减少,并增加驱动免疫激活和炎症的病毒血症。最后,在我们的初步发现的指导下,可以模仿正常HDL(HDL模拟)功能的药物可以在HIV-1感染受试者的体外改善HDL功能,我们将研究在体外施用HDL模拟物,是否可以减少HIV诱导的免疫激活和HIV-1-1 Intectitive(HIV诱导)是否可以降低HIV诱导的受试者。拟议的研究中要生成的数据将允许确定氧化的HDL是否是HIV-1,免疫激活和动脉粥样硬化之间的新机械联系。这项研究的长期目标是为进一步研究的基础奠定基础,该研究是否可以在HIV感染中使用HDL Mimetics。
相关性:与普通人群相比,接受抗病毒治疗的HIV感染患者过早地死于心血管疾病(CVD),但是将HIV感染,CVD和免疫系统激活(免疫激活)联系起来的机制仍然未知。该研究建议旨在研究在HIV感染中观察到的全身性炎症期间产生的异常脂蛋白是否可以介导HIV,免疫系统和CVD之间的串扰。我们预计这项为期5年的研究将提高我们对与HIV相关的免疫激活和CVD发病机理的理解,这些发现可能会引发进一步的研究,以探索新型治疗干预措施的疗效,从而改善了HIV感染患者的预后。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Theodoros Kelesidis其他文献
Theodoros Kelesidis的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Theodoros Kelesidis', 18)}}的其他基金
Mitoquinone/mitoquinol mesylate as oral and safe Postexposure Prophylaxis for Covid-19
米托醌/甲磺酸米托喹诺作为 Covid-19 的口服且安全的暴露后预防
- 批准号:
10727092 - 财政年份:2023
- 资助金额:
$ 17.84万 - 项目类别:
Targeting early instigators of vascular inflammation to prevent and/or delay vascular aging in chronic treated HIV
针对血管炎症的早期诱发因素,预防和/或延缓长期治疗的艾滋病毒患者的血管老化
- 批准号:
10413007 - 财政年份:2018
- 资助金额:
$ 17.84万 - 项目类别:
Preclinical studies to establish the combination of apoA-I mimetic peptides and statins as novel therapy for COVID-19
建立 apoA-I 模拟肽和他汀类药物组合作为 COVID-19 新疗法的临床前研究
- 批准号:
10456506 - 财政年份:2018
- 资助金额:
$ 17.84万 - 项目类别:
Targeting early instigators of vascular inflammation to prevent and/or delay vascular aging in chronic treated HIV
针对血管炎症的早期诱发因素,预防和/或延缓长期治疗的艾滋病毒患者的血管老化
- 批准号:
9789142 - 财政年份:2018
- 资助金额:
$ 17.84万 - 项目类别:
Targeting early instigators of vascular inflammation to prevent and/or delay vascular aging in chronic treated HIV
针对血管炎症的早期诱发因素,预防和/或延缓长期治疗的艾滋病毒患者的血管老化
- 批准号:
10213618 - 财政年份:2018
- 资助金额:
$ 17.84万 - 项目类别:
Targeting early instigators of vascular inflammation to prevent and/or delay vascular aging in chronic treated HIV
针对血管炎症的早期诱发因素,预防和/或延缓长期治疗的艾滋病毒患者的血管老化
- 批准号:
9980751 - 财政年份:2018
- 资助金额:
$ 17.84万 - 项目类别:
Humanized mice as a model to study the role of oxidized lipids in HIV-related cardiovascular disease
人源化小鼠作为模型研究氧化脂质在艾滋病毒相关心血管疾病中的作用
- 批准号:
9203331 - 财政年份:2016
- 资助金额:
$ 17.84万 - 项目类别:
Oxidized HDL in the intersection of HIV, immune activation and atherosclerosis
HIV、免疫激活和动脉粥样硬化交叉点中的氧化 HDL
- 批准号:
9313176 - 财政年份:2013
- 资助金额:
$ 17.84万 - 项目类别:
Oxidized HDL in the intersection of HIV, immune activation and atherosclerosis
HIV、免疫激活和动脉粥样硬化交叉点中的氧化 HDL
- 批准号:
8600028 - 财政年份:2013
- 资助金额:
$ 17.84万 - 项目类别:
Oxidized HDL in the intersection of HIV, immune activation and atherosclerosis
HIV、免疫激活和动脉粥样硬化交叉点中的氧化 HDL
- 批准号:
9097645 - 财政年份:2013
- 资助金额:
$ 17.84万 - 项目类别:
相似国自然基金
靶向HDAC3/SIAH2蛋白复合物的HDAC3降解剂的作用机制、结构改造及非酶活功能介导的抗炎活性研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
卡萨烷选择性调控糖皮质激素受体GR功能的抗炎作用机制与新颖调控剂的设计与发现
- 批准号:82273824
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
靶向HDAC3/SIAH2蛋白复合物的HDAC3降解剂的作用机制、结构改造及非酶活功能介导的抗炎活性研究
- 批准号:82204218
- 批准年份:2022
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
ZAP-70选择性共价抑制剂及降解剂的设计合成和抗炎活性研究
- 批准号:82103973
- 批准年份:2021
- 资助金额:24.00 万元
- 项目类别:青年科学基金项目
ZAP-70选择性共价抑制剂及降解剂的设计合成和抗炎活性研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Using trained immunity-inhibiting nanobiologics to achieve tolerance of heart allografts in non-human primates
使用经过训练的免疫抑制纳米生物制剂来实现非人类灵长类动物同种异体心脏移植的耐受性
- 批准号:
10642598 - 财政年份:2023
- 资助金额:
$ 17.84万 - 项目类别:
Mechanisms of Metal Ion Homeostasis of Oral Streptococci
口腔链球菌金属离子稳态机制
- 批准号:
10680956 - 财政年份:2023
- 资助金额:
$ 17.84万 - 项目类别:
Prevention of intracellular infection in diabetic wounds by commensal Staphylococcus epidermidis
共生表皮葡萄球菌预防糖尿病伤口细胞内感染
- 批准号:
10679628 - 财政年份:2023
- 资助金额:
$ 17.84万 - 项目类别:
Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)
开发 CM-CS1 CAR Treg 治疗肌萎缩侧索硬化症 (ALS)
- 批准号:
10696512 - 财政年份:2023
- 资助金额:
$ 17.84万 - 项目类别:
Novel first-in-class Therapeutics for Rheumatoid Arthritis
类风湿关节炎的一流新疗法
- 批准号:
10696749 - 财政年份:2023
- 资助金额:
$ 17.84万 - 项目类别: